SEC Company Response from AEON Biopharma, (AEON) — Feb 12, 2026
AEON Biopharma, Inc.
Date: Feb. 12, 2026 · CIK: 0001837607 · Accession: 0001104659-26-014404
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-293309
Letter
Re: AEON Biopharma, Inc. Registration Statement on Form S-3 (Registration No. 333-293309)
February 12, 2026
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549-6010
Request for Acceleration of Effective Date
To the addressee set forth above:
In accordance with Rule 461 under the Securities Act of 1933, as amended, we hereby request acceleration by the Securities and Exchange Commission (the " Commission ") of the effective date of the above-referenced Registration Statement on Form S-3 (Registratiom No. 333-293309) (the " Registration Statement ") of AEON Biopharma, Inc. We respectfully request that the Registration Statement become effective as of 5:30 p.m., Washington, D.C. time, on February 17, 2026, or as soon as practicable thereafter.
The Company requests that we be notified of such effectiveness by a telephone call to Drew Capurro of Latham & Watkins LLP at (714) 755-8008 that such effectiveness also be confirmed in writing.
Sincerely,
AEON Biopharma, Inc.
Show Raw Text
CORRESP 1 filename1.htm February 12, 2026 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549-6010 Re: AEON Biopharma, Inc. Registration Statement on Form S-3 (Registration No. 333-293309) Request for Acceleration of Effective Date To the addressee set forth above: In accordance with Rule 461 under the Securities Act of 1933, as amended, we hereby request acceleration by the Securities and Exchange Commission (the " Commission ") of the effective date of the above-referenced Registration Statement on Form S-3 (Registratiom No. 333-293309) (the " Registration Statement ") of AEON Biopharma, Inc. We respectfully request that the Registration Statement become effective as of 5:30 p.m., Washington, D.C. time, on February 17, 2026, or as soon as practicable thereafter. The Company requests that we be notified of such effectiveness by a telephone call to Drew Capurro of Latham & Watkins LLP at (714) 755-8008 that such effectiveness also be confirmed in writing. Sincerely, AEON Biopharma, Inc. By: /s/ Alex Wilson Name: Alex Wilson Title: Chief Legal & Strategy Officer cc: Via Email Robert Bancroft, AEON Biopharma, Inc. Drew Capurro, Esq., Latham & Watkins LLP